We’re on a Mission to Improve the Human Condition

Combining cutting-edge data science and human genetics, we’re creating precision medicines to fight debilitating diseases.

Learn About Our Company
IT’S ALL POSSIBLE.

We leverage an innovative drug discovery model to accelerate the identification of novel molecular targets and create effective precision medicine treatments with more efficiency than ever before.

We’re Rewriting the Narrative
to Change the Future

Neuron23 Envisions a World Where Every Disease has a Treatment Through Breakthrough Science, Powered by Personalized Medicine

Our Science

Meet the Heart of Neuron23

We're a diverse team with proven success in both science and business, driven by one common goal: enhancing and improving the lives of the patients we serve. Compassion is at our core, and we're on a never-ending mission to create the type of breakthroughs that can propel the world forward.

Meet Our Team

Latest News

  • NEWS /

    Neuron23 Announces First-in-human Dose in Phase 1 Clinical Trial of NEU-111, a TYK2 Inhibitor with Best-in-class Potential for Immune-mediated Inflammatory Disorders

    SOUTH SAN FRANCISCO, Calif. – December 3, 2024 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the recent initiation of dosing in a Phase 1 clinical trial of NEU-111 in healthy volunteers. NEU-111 is a potent and highly selective oral allosteric inhibitor […]

    Read More
  • NEWS /

    Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease

    NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease Global Phase 2 clinical trial leverages Roche-developed digital biomarker as primary endpoint for enhanced precision and efficiency over traditional clinical rating scales Collaborations with QIAGEN, Sano Genetics and Quest Diagnostics to […]

    Read More
  • NEWS /

    Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial

    Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease SOUTH SAN FRANCISCO, Calif., November 19, 2024 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced a collaboration with Roche to […]

    Read More
See All News

Be in the Room When History is Made

We're looking for team members with an insatiable hunger for creating change and the talent to make it happen — those ready to meet us where we are and excited to help take us where we want to go.

Current Opportunities